NCT03084250Unknown4 期
A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
Shanghai Nanhui Nanhua Hospital1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2017年3月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Number of subjects who develop to hepatocellular carcinoma during 5 years
研究概览
简要总结
The CHB subjects who are cirrhosis, will be randomized to two groups.
The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.
The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.
详细描述
This study is a prospective, randomized, open-label study.
The CHB subjects who are cirrhosis will be randomized to two groups.
The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.
The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients with age ≥18 and ≤65 years;
- •There should be evidences that HBsAg has been positive for more than 6 months with HBsAb and HBeAb negative; HBV-related cirrhosis
- •Women without ongoing pregnancy or breast feeding and both women and men willing to take an effective contraceptive measure during the treatment;
- •Agree to participate in the study and sign the patient informed consent form.
排除标准
- •Treated by immunosuppressant,immunomodulator,Systemic cytotoxic drug,herbs or HBIg within 6 months prior to the first dose of treatment;
- •ALT≥10 X ULN or total bilirubin ≥2 X ULN;
- •Allergic history to interferon;
- •Co-infection with active hepatitis A, hepatitis C, hepatitis D and/or human immunodeficiency virus (HIV);
- •Child-Pugh scores >7;
- •History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures, thalassemia);
- •Pregnant or breast-feeding Women;
- •Consuming alcohol in excess of 20g/day for women and 30g/day for men within 6 months prior to enrollment or drug taking history;
- •ANC(absolute neutrophil count)<1.5x 10^9/L or PLT(platelet count)<90x 10^9/L
- •Creatinine over upper limit of normal;
- •History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as major depression or psychosis that treated with antidepressant medication or a major tranquilizer at therapeutic doses respectively at any time prior to 3 months or any history of the following: a suicidal attempt hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease;
- •History of immunologically mediated disease, (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis etc.);
- •History of esophageal varices bleeding or other evidence of esophageal varices bleeding or other symptoms consistent with decompensated liver disease;
- •History of severe cardiac disease (e.g., New York Heart Association Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases);
- •Hemodialysis patients or patients with renal insufficiency;
- •History of a severe seizure disorder or current anticonvulsant use;
- •Major organ transplantation or other evidence of severe illness, malignancy, or any other conditions, which would make the patient, in the opinion of the investigator, unsuitable for the study;
- •History of thyroid disease poorly controlled on prescribed medications;
- •Evidence of severe retinopathy or clinically relevant ophthalmologic disorder;
- •History of other severe disease or evidence of other severe disease or any other illness or conditions that the investigator believe that patients are not suitable to join in the study;
- •Patients included in another trial or having been given investigational drugs within 12 weeks prior to screening;
- •AFP(alpha feto protein)>50ng/ml and/or evidence of hepatocellular carcinoma;
- •Patients treated with Telbivudine;
- •Other disease should exclusive considered by the investigator.
研究组 & 干预措施
Combination
Experimental
The subjects will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a
干预措施: Peginterferon Alfa-2A (Drug)
nucleotide analogue
Active Comparator
The subjects will be treated by nucleotide analogue (NA) only
干预措施: Adefovir, entecavir,tenofovir, either of them (Drug)
结局指标
主要结局
Number of subjects who develop to hepatocellular carcinoma during 5 years
时间窗: 5 years
The number of subjects develop to hepatocellular carcinoma during 5 years will be measured
次要结局
- Number of participants who achieve HBeAg loss and HBeAg seroconversion(year 1,2,3,4,5)
- Number of participants who achieve HBsAg loss and HBsAg seroconversion(year 1,2,3,4,5)
- The factor such as HBsAg level related to the incidence of HCC development(year 1)
研究者
Chenbo Hu
Dr.Chenbo Hu
Shanghai Nanhui Nanhua Hospital
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)Liver DiseasesHypertension, PortalNCT05282121Boehringer Ingelheim90
已完成
3 期
Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV SubjectsHCVHepatitis CNCT03092375University of Florida177
已完成
1 期
Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With CirrhosisHepatic CirrhosisNCT00896597Norgine240
已完成
4 期
A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-InfectionHBV/HCV Co-infectionNCT02339337Kaohsiung Medical University Chung-Ho Memorial Hospital203
已完成
不适用
HIFU Ablation vs Fixed-dose RAI-131 Therapy in Moderate-sized Non-toxic MNGNon Toxic Multinodular GoiterHigh Intensity Focused UltrasoundRAINCT04009863The University of Hong Kong156